Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
5.03
0.00 (0.00%)
Mar 12, 2026, 1:23 PM EDT - Market open
Lisata Therapeutics Employees
Lisata Therapeutics had 26 employees as of December 31, 2024. The number of employees increased by 1 or 4.00% compared to the previous year.
Employees
26
Change (1Y)
1
Growth (1Y)
4.00%
Revenue / Employee
$41,154
Profits / Employee
-$701,615
Market Cap
44.37M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 26 | 1 | 4.00% |
| Dec 31, 2023 | 25 | -2 | -7.41% |
| Dec 31, 2022 | 27 | 0 | - |
| Dec 31, 2021 | 27 | 3 | 12.50% |
| Dec 31, 2020 | 24 | -3 | -11.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 70 |
| NextCure | 43 |
| Atara Biotherapeutics | 38 |
| Palatin Technologies | 29 |
| Lipocine | 16 |
| CervoMed | 15 |
| Apollomics | 13 |
| Telomir Pharmaceuticals | 9 |
LSTA News
- 5 days ago - Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. - GlobeNewsWire
- 6 weeks ago - Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide - GlobeNewsWire
- 7 weeks ago - Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer - GlobeNewsWire
- 4 months ago - Lisata Therapeutics, Inc. (LSTA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year' - GlobeNewsWire
- 4 months ago - Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent - GlobeNewsWire
- 4 months ago - Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 - GlobeNewsWire